Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ionyte appears to be a **proprietary mineral and electrolyte liquid product** sold by Basic Reset and associated with Biogenyx, rather than a well-characterized approved pharmaceutical active ingredient. Publicly available sources indicate it was marketed with disease-related claims and later included in FDA recall actions involving unapproved drugs distributed by Basic Reset and Biogenyx. The exact active composition, validated mechanism of action, approved indication, and standard pharmacology are not clearly established in reliable regulatory or scientific sources, so it is best characterized as an unapproved and poorly specified mineral-electrolyte preparation rather than a defined modern therapeutic drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ionyte.